Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant's Ancure

This article was originally published in The Gray Sheet

Executive Summary

FDA is permitting implants of the abdominal aortic aneurysm stent graft on a "compassionate use" basis while the company conducts a recall of the product from hospitals, Guidant reports following a March 23 meeting with FDA. Problems related to the deployment of the minimally invasive system led to a March 16 announcement that the company would stop production and sales of the device (1"The Gray Sheet" March 19, 2001, In Brief) and take a $12-15 mil. charge to first-quarter earnings. Discussions with FDA are ongoing, Guidant says
Advertisement

Related Content

Guidant 's Ancure
Guidant 's Ancure
Advertisement
UsernamePublicRestriction

Register

MT014680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel